Thermo Fisher Bioproduction Insights

1. The Future Of RNA Manufacturing Starts With Raw Material Innovation 2/11/2026

   Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

2. Reframing Residual DNA Testing: What It Is--And What It Isn't 2/11/2026

   Residual host-cell DNA quantitation requires sensitive, well-validated analytical workflows to ensure accurate impurity control, process understanding, and regulatory compliance in complex biologics.

3. Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy 2/6/2026

   The most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.

4. Integrated Upstream And Downstream Strategies For Robust mAb Manufacturing 2/5/2026

   Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability, optimize quality, and ensure reliable technology transfer across biomanufacturing scales.

5. Multispecific Antibodies: Key Challenges And Solutions To Enable A New Frontier In Cancer Treatment 11/14/2025

   Multispecific antibodies are a newer class of cancer therapeutics addressing tumor complexity. Learn about the design, manufacturing, and regulatory challenges and integrated solutions accelerating their development.

6. Industry 5.0: Preparing For The Future Of Biotechnology 11/14/2025

   Industry 5.0 represents the next generation of bioproduction—the Adaptive Plant—where human expertise is empowered by AI-enabled insights, autonomous systems, and strategic collaboration.

7. Develop A Cost-Effective cGMP Chemical Sourcing Strategy 11/4/2025

   Outsourcing your cGMP chemical supply chain can significantly reduce capital and operating expenses, minimize production delays, and boost manufacturing productivity through improved sourcing and logistics.

8. Leveraging 3 Distinct Resins To Provide Effective Impurity Removal For mAbs And Novel Antibody Derivatives 11/3/2025

   Due to the complexity of bispecifics, Fc-fusion proteins, and Fab fragments, their manufacturing poses added purification challenges and requires a robust toolkit of purification techniques.

9. Considerations For Buffer Preparation As You Grow 10/29/2025

   Buffer preparation strategies impact cost, efficiency, and risk. This infographic compares in-house vs. outsourced approaches, helping teams align supply decisions with growth, operational needs, and long-term production goals.

10. How To Mitigate Particulate Contamination In cGMP 10/28/2025

    Maintaining cGMP standards, controlling particulate contamination ensures drug safety, quality, effectiveness, and shelf life while preventing immune reactions and regulatory noncompliance.